What are Acadia Pharmaceuticals' share price targets?

16 analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price targets range from $19.00 to $42.00. On average, they predict the company's share price to reach $28.94 in the next year. This suggests a possible upside of 89.8% from the stock's current price.

What does Acadia Pharmaceuticals Inc (ACAD) do?

The Company specializes in the treatment of induced dysfunction in parkinson's disease, schizophrenia, neuropathic pain, and glaucoma. Stock analysis for ACADIA Pharmaceuticals Inc (ACAD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Who owns Acadia Pharmaceuticals Inc?

Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. ACAD | Complete ACADIA Pharmaceuticals Inc. stock news by MarketWatch.